Use of bormperidol in psychotic outpatients.
An ambulatory population of 18 men and 4 women, aged 17 to 61 years (mean 30.3), were treated with bromperidol oral drops for an eight-week study period.


OBJECTIVE
investigation of tolerability, side effects and psychopharmacological effects; determination of the optimal dose. The Wirtschafts Mathematik AG Zurich case report form was used. Various medical, neurological and psychic parameters were recorded before the study and after the first, second, fourth, sixth and eighth weeks of treatment. Bromperidol is a potent and safe neuroleptic agent of polyvalent action, which can be administered in one single daily dose and is very well tolerated in ambulatory conditions, without antiparkinsonians in the doses used.
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*
D006220:Haloperidol